CTX as an early prediction on bone loss in women on aromatase inhibitors: the B-ABLE cohort study

CTX as an early prediction on bone loss in women on aromatase inhibitors: the B-ABLE cohort study

Manylion Llyfryddiaeth
Prif Awduron:	Torres-Del-Pliego, E, Prieto-Alhambra, D, Servitja, S, Soriano-Tomas, R, Gonzalez-Maeso, I, Garcia-Giralt, N, Rodriguez-Sanz, M, Diez-Perez, A, Tusquets, I, Nogues, X
Fformat:	Journal article
Cyhoeddwyd:	2013

Eitemau Tebyg

Genetic determinants of aromatase inhibitor-related arthralgia: The B-ABLE cohort study
gan: Garcia-Giralt, N, et al.
Cyhoeddwyd: (2013)

Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study.
gan: Garcia-Giralt, N, et al.
Cyhoeddwyd: (2013)

Genetic determinants of bone mineral density loss in Aromatase inhibitors treatment
gan: Rodriguez-Sanz, M, et al.
Cyhoeddwyd: (2013)

Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study.
gan: Prieto-Alhambra, D, et al.
Cyhoeddwyd: (2012)

Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study.
gan: Prieto-Alhambra, D, et al.
Cyhoeddwyd: (2012)

Vitamin D repletion and aromatase inhibitor-related bone loss in women non treated with bisphosphonates
gan: Prieto-Alhambra, D, et al.
Cyhoeddwyd: (2011)

Increased fracture risk in women treated with aromatase inhibitors versus tamoxifen: Beneficial effect of bisphosphonates
gan: Pineda-Moncusí, M, et al.
Cyhoeddwyd: (2019)

Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance
gan: Sonia Servitja, et al.
Cyhoeddwyd: (2015-09-01)

Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
gan: Nogues, X, et al.
Cyhoeddwyd: (2010)

Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer
gan: Servitja, S, et al.
Cyhoeddwyd: (2012)

Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer.
gan: Servitja, S, et al.
Cyhoeddwyd: (2012)

Long-term effect of aromatase inhibitors on fracture risk compared to tamoxifen: A “real world” cohort study of continued treatment up to ten years of follow-Up
gan: Pineda-Moncusi, M, et al.
Cyhoeddwyd: (2018)

Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study.
gan: Prieto-Alhambra, D, et al.
Cyhoeddwyd: (2011)

Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study.
gan: Prieto-Alhambra, D, et al.
Cyhoeddwyd: (2011)

Comparison of the effects of exemestane versus letrozole on bone loss: A cohort study
gan: Prieto-Alhambra, D, et al.
Cyhoeddwyd: (2011)

Effect of vitamin D supplementation on aromatase inhibitor-related musculoskeletal side effects for breast cancer: B-ABLE cohort
gan: Pineda-Moncusí, M, et al.
Cyhoeddwyd: (2021)

Evolución de la DMO durante el tratamiento con inhibidores de aromatasa y su relación con el gen CYP11A1: estudio prospectivo de la cohorte B-ABLE
gan: Rodríguez-Sanz M, et al.
Cyhoeddwyd: (2015-11-01)

Estudio de la base genética de la reducción del Trabecular Bone Score relacionada con los inhibidores de la aromatasa
gan: Pineda-Moncusí M, et al.
Cyhoeddwyd: (2018-10-01)

Aromatase inhibitor-induced arthralgia: is vitamin D deficiency responsible?
gan: Prieto-Alhambra, D, et al.
Cyhoeddwyd: (2011)

Aromatase inhibitor-induced arthralgia: Is vitamin D deficiency responsible?
gan: Prieto-Alhambra, D, et al.
Cyhoeddwyd: (2011)

Persistencia a los inhibidores de la aromatasa en la cohorte SIDIAP: mortalidad e influencia de los bifosfonatos
gan: Pineda-Moncusí M, et al.
Cyhoeddwyd: (2020-08-01)

Análisis genético de enzimas de la vía esteroidal asociadas a efectos adversos musculoesqueléticos delos inhibidores de la aromatasa
gan: Pineda-Moncusí M, et al.
Cyhoeddwyd: (2017-06-01)

Aromatase Activity and Bone Loss in Men
gan: Daniela Merlotti, et al.
Cyhoeddwyd: (2011-01-01)

Most women with breast cancer about to initiate aromatase inhibitors already have bone loss
gan: R. Hernández San Gil, et al.
Cyhoeddwyd: (2021-01-01)

Construction and validation of a risk prediction model for aromatase inhibitor-associated bone loss
gan: Meiling Chu, et al.
Cyhoeddwyd: (2023-04-01)

Guidelines for diagnostics and treatment of aromatase inhibitor-induced bone loss in women with breast cancer
gan: Elona Juozaitytė, et al.
Cyhoeddwyd: (2014-01-01)

Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer
gan: Bauer M, et al.
Cyhoeddwyd: (2012-06-01)

Bone health history in breast cancer patients on aromatase inhibitors.
gan: Marilyn L Kwan, et al.
Cyhoeddwyd: (2014-01-01)

Aromatase inhibitors in the treatment of endometriosis
gan: Radosław Słopień, et al.
Cyhoeddwyd: (2016-03-01)

Aromatase inhibitors in male sex
gan: Santosh Kumar Singh
Cyhoeddwyd: (2013-01-01)

Natural Inhibitors of the Aromatase Enzyme
gan: Roberto R. Gil
Cyhoeddwyd: (2000-03-01)

Molecular Docking of Aromatase Inhibitors
gan: Virapong Prachayasittikul, et al.
Cyhoeddwyd: (2011-04-01)

Long term effects of aromatase inhibitor treatment in patients with aromatase excess syndrome
gan: Eleni Z. Giannopoulou, et al.
Cyhoeddwyd: (2024-11-01)

The effect of third-generation aromatase inhibitors on aromatase avtivity in visceral adipose tissue
gan: D. V. Lytkin, et al.
Cyhoeddwyd: (2018-08-01)

X-linked hypophosphatemic rickets with advanced bone age treated with aromatase inhibitor
gan: João Felipe Queiroz, et al.
Cyhoeddwyd: (2023-05-01)

AROMATASE INHIBITORS IN BREAST CANCER THERAPY
gan: Hande Karahan, et al.
Cyhoeddwyd: (2011-04-01)

Aromatase inhibitors in stimulated IVF cycles
gan: Tournaye Herman, et al.
Cyhoeddwyd: (2011-06-01)

Aromatase inhibitors in the treatment of deep endometriosis
gan: Simone Ferrero, et al.
Cyhoeddwyd: (2009-09-01)

Aromatase inhibitors in post-menopausal endometriosis
gan: Devroey Paul, et al.
Cyhoeddwyd: (2011-06-01)

Indices in dental image exams for bone mineral density evaluation of aromatase inhibitor users
gan: Sâmila Gonçalves Barra, et al.
Cyhoeddwyd: (2022-12-01)